Promoter methylation of INK4a/ARF as detected in bile-significance for the differential diagnosis in biliary disease

Clinical Cancer Research

Volumn 9, Issue 5, 2003, Pages 1773-1778

  Klump, Bodo ^a   Hsieh, Chih Jen ^a   Dette, Stephan ^a   Holzmann, Karlheinz ^a   Kießlich, Ralf ^b   Jung, Michael ^b   Sinn, Udo ^e   Ortner, Marianne ^c   Porschen, Rainer ^d   Gregor, Michael ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b St Hildegardis Krankenhaus   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d Hospital Bremen East   (Germany)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSYLATION FACTOR; GENOMIC DNA; PROTEIN P14; PROTEIN P16;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; BILIARY TRACT CANCER; BILIARY TRACT DISEASE; CANCER DIAGNOSIS; DIFFERENTIAL DIAGNOSIS; DNA METHYLATION; GALLBLADDER CARCINOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; TUMOR SUPPRESSOR GENE;

ADULT; AGED; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; CHOLEDOCHOLITHIASIS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DIAGNOSIS, DIFFERENTIAL; DNA METHYLATION; DNA, NEOPLASM; GALLBLADDER DISEASES; GENE SILENCING; HUMANS; MIDDLE AGED; PROGNOSIS; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P14ARF;

EID: 0038327718     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Parker, S. L., Tong, T., Bolden, S., and Wingo, P. A. Cancer Statistics 1996. CA Cancer J. Clin., 65: 5-27, 1996.
2. Hatfield, A. R. W., Smithies, A., Wilkins, R., and Levi, A. J. Assessment of endoscopic retrograde cholangiopancreatography (ERCP) and pure pancreatic juice cytology in patients with pancreatic disease. Gut, 17: 14-21, 1976.
3. Ferrari, A. P., Lichtenstein, D. R., Slivka, A., Chang, C., and CarrLocke, D. L. Brush cytology during ERCP for the diagnosis of biliary and pancreatic malignancies. Gastrointest. Endosc., 40: 140-145, 1994.
4. Lee, Y. M., and Kaplan, M. M. Primary sclerosing cholangitis. N. Engl. J. Med., 332: 924-933, 1995.
5. Aadland, E., Schrumpf, E., Fausa, O., Elgjo, K., Heilo, A., Aakhus, T., and Gjone, E. Primary sclerosing cholangitis: a long-term follow-up study. Scand. J. Gastroenterol., 22: 655-664, 1987.
6. Rosen, C. B., and Nagomey, D. M. Cholangiocarcinoma complicating primary sclerosing cholangitis. Semin. Liver Dis., 11: 26-30, 1991.
7. Wiesner, R. H., Porayko, M. K., Dickson, E. R., Gores, G. J., LaRusso, N. F., Hay, J. E., Wahlstrom, H. E., and Krom, R. A. Selection and timing of liver transplantation in primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology, 16: 1290-1299, 1992.
8. Shetty, K., Rybicki, L., and Carey, W. D. The Child-Pugh classification as a prognostic indicator for survival in primary sclerosing cholangitis. Hepatology, 25: 1049-1053, 1997.
9. Marsh, J. W., Iwatsuki, S., Makowka, L., Esquivel, C. O., Gordon, R. D., Todo, S., Tzakis, A., Miller, C., Van-Thiel, D., and Starzl, T. E. Orthotopic liver transplantation for primary sclerosing cholangitis, Ann. Surg., 207: 21-25, 1988.
10. Stieber, A. C., Marino, I. R., Iwatsuki, S., and Starzl, T. E. Cholangiocarcinoma in sclerosing cholangitis. The role of liver transplantation. Int. Surg., 74: 1-3, 1989.
11. Farrant, J. M., Hayllar, K. M., Wilkinson, M. L., Karani, J., Portmann, B. C., Westaby, D., and Williams, R. Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology, 100: 1710-1717, 1991.
12. Miros, M., Kerlin, P., Walker, N., Harper, J., Lynch, S., and Strong, R. Predicting cholangiocarcinoma in patients with primary sclerosing cholangitis before liver transplantation. Gut, 32: 1369-1373, 1991.
13. Nashan, B., Schlitt, H. J., Tusch, G., Oldhafer, K. J., Ringe, B., Wagner, S., and Pichlmayr, R. Biliary malignancies in primary sclerosing cholangitis: timing for liver transplantation. Hepatology, 23: 1105-1111, 1996.
14. Sherr, C. J. Cancer cell cycles. Science (Wash. DC), 276: 1672-1677, 1996.
15. Chin, L., Pomerantz, J., and DePinho, R. A. The INK4a/ARF tumor suppressor: one gene-two products-two pathways. Trends Biochem. Sci., 23: 291-296, 1998.
16. Merlo, A., Herman, J. G., Mao, L., Lee, D. J., Gabrielson, E., Burger, P. C., Baylin, S. B., and Sidransky, D. 5′CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med., 7: 686-692, 1995.
17. Kamb, A. Cell-cycle regulators and cancer. Trends Genet., 11: 136-140, 1995.
18. Quelle, D. E., Zindy, F., Ashmun, R. A., and Sherr, C. J. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell, 83: 993-1000, 1995.
19. Kamijo, T., Weber, J. D., Zambetti, G., Zindy, F., Roussel, M. F., and Sherr, C. J. Functional and physical interactions of the ARF tumor suppressor with p53 and MDM2. Proc. Natl. Acad. Sci., 95: 8292-8297, 1998.
20. Herman, J. G., Merlo, A., Mao, L., Lapidus, R. G., Issa, J. P., Davidson, N. E., Sidransky, D., and Baylin, S. B. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation an all common human cancers. Cancer Res., 55: 4525-4530, 1995.
21. Liggett, W. H., and Sidransky, D. Role of the p16 tumor suppressor gene in cancer. J. Clin. Oncol., 16: 1197-1206, 1998.
22. Robertson, K. D., and Jones, P. A. The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53. Mol. Cell. Biol., 18: 6457-6473, 1998.
23. INK4a methylation and p53 mutational status. Cancer Res., 60: 129-133, 2000.
24. Barrett, M. T., Sanchez, C. A., Galipeau, P. C., Neshat, K., Emond, M., and Reid, B. J. Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus. Oncogene, 13: 1867-1873, 1996.
25. INK4a tumor suppressor gene during neoplastic progression in Barrett's esophagus. Gastroenterology, 115: 1381-1386, 1998.
26. INK4a promoter in colectomy specimen of patients with longstanding and extensive ulcerative colitis. Cancer Res., 58: 3942-3945, 1998.
27. Tannapfel, A., Benicke, M., Katalinic, A., Uhlmann, D., Köckerling, F., Hauss, J., and Wittekind. C. Frequency of p16INK4a alterations and k-ras mutations in intrahepatic cholangiocarcinoma of the liver. Gut, 47: 721-727, 2000.
28. Herman, J. G., and Graff, J, R., Myohänen, S. Nelkin, B., Baylin, S. B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA, 93: 9821-9826, 1996.
29. Yanagisawa, A., Ohtake, K., Ohashi, K., Hori, M., Kitagawa, T., Sugano, H., and Kato, Y. Frequent c-Ki-ras oncogene activation in mucous cell hyperplasias of pancreas suffering from chronic inflammation. Cancer Res., 53: 953-956, 1993.
30. Tada, M., Ohashi, M., Shiratori, Y., Okudaira, T., Komatsu, Y., Kawabe, T., Yoshida, H., Machinami, R., Kishi, K., and Omato, M. Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease. Gastroenterology, 110: 227-231, 1996.
31. Kersting, M., Friedl, C., Kraus, A., Behn, M., Pankow, W., and Schuermann, M. Differential frequencies of p16INK4a promoter hypermethylation, p53 mutation, and k-ras mutation in exfoliative material mark the development of lung cancer in symptomatic chronic smokers. J. Clin. Oncol., 18: 3221-3229, 2000.